Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page
Provident Healthcare Partners Provident Healthcare Partners

Q1-2023 Oncology Services Update

Provident Healthcare Partners
Skip to the end of the Expertise Menu

Q1-2023 Oncology Services Update

Despite only two transactions closing in the first quarter of 2023, Provident continues to see great upside and potential for acquirers and sellers alike in the oncology space due to a combination of a growing need of care and a high degree of market fragmentation among community-based oncology providers across the United States. Throughout 2023, we expect two primary themes to play out; first, strategic acquirers, both public and private equity-backed, will continue to lead transaction volume via add-on acquisitions, and second, the space will see a swift march into the next investment life cycle phase, characterized by an uptick in secondary transactions.

According to an article published by Bloomberg, General Atlantic is exploring the sale of OneOncology, a transaction that could receive more than $2 billion in enterprise value. OneOncology has been one of the most active consolidators, having acquired 15+ community-based practices and expanding its services across 175 sites and more than 12 states since General Atlantic’s investment in 2018.

We have not seen a new oncology platform since 2018, when we saw four private equity firms create oncology platforms. Over the past 5 years, consolidation has been driven by strategic acquirers, including hospital and health system acquisitions. Given the sheer amount of add-on activity and the fact that several platforms are five years into their investment period, Provident believes 2023 could be characterized by a rise in secondary buyouts as investors wait to see what transpires with OneOncology.

Furthermore, The US Oncology Network remained active with two add-on acquisitions in the first quarter of 2023, both of which were multidisciplinary in nature. The shift to new subspecialties for USON will be an interesting trend to follow as the Company looks to enable more comprehensive care across their network.

To print and download the full Oncology Update report, please click below…

[holo_button icon=”/wp-content/uploads/2023/04/Q1-2023-Oncology-Newsletter.pdf”” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]